Fluxome to Supply Resveratrol for Five-Year Human Clinical

February 8, 2011

Ingredient supplier Fluxome A/S (Stenløse, Denmark) has announced that it will provide resveratrol for an upcoming Danish study on resveratrol and long-term human use.

Ingredient supplier Fluxome A/S (Stenløse, Denmark) has announced that it will provide resveratrol for an upcoming Danish study on resveratrol and long-term human use.

Resveratrol is a polyphenol ingredient found in red wine and it is believed to promote a number of health benefits, including longevity and heart health.

The Danish Council for Strategic Research will fund the five-year project, which will be a collaboration of researchers from four Danish universities and Pennsylvania State University. Patients will be assigned to 12 months of daily supplementation with Fluxome resveratrol. The study begins in June.

Fluxome has provided details on the study’s mission at its website:

The objective of the project is to prove that resveratrol in humans can neutralize the detrimental effect of obesity on the whole body metabolism such as low-grade chronic inflammation, insulin resistance, and lipid infiltration/inflammation in liver and skeletal muscle. Low-grade inflammation is associated with type 2 diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and osteoporosis. Resveratrol has strong anti-inflammatory effects and is a promising compound with the potential to neutralize obesity-induced diseases and osteoporosis. The new project focuses on the effect of resveratrol on insulin sensitivity, inflammation, bone and fatty liver disease in a long-term study in humans. Pre-clinical trials have demonstrated that one effect of resveratrol is reduction of inflammation and the same effect is expected to be seen in humans.